Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

Zattarin, Emma; Presti, Daniele; Mariani, Luigi; Sposetti, Caterina; Leporati, Rita; Menichetti, Alice; Corti, Chiara; Benvenuti, Chiara; Fucà, Giovanni; Lobefaro, Riccardo; Ligorio, Francesca; Provenzano, Leonardo; Vingiani, Andrea; Del Vecchio, Marta; Griguolo, Gaia; Sirico, Marianna; Bernocchi, Ottavia; Marra, Antonio; Zagami, Paola; Agostinetto, Elisa; Jacobs, Flavia; Di Mauro, Pierluigi; Esposito, Andrea; Giorgi, Carlo Alberto; Lalli, Luca; Boldrini, Laura; Giacchetti, Pier Paolo Berton; Schianca, Ambra Carnevale; Guarneri, Valentina; Pedersini, Rebecca; Losurdo, Agnese; Zambelli, Alberto; Generali, Daniele; Criscitiello, Carmen; Curigliano, Giuseppe; Pruneri, Giancarlo; de Braud, Filippo; Dieci, Maria Vittoria; Vernieri, Claudio

doi:doi/10.1038/s41523-023-00534-1

Recherche avancée | Historique de recherche Mon DI-fusion | À propos de DI-fusion | Contact |

Citer

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

Article révisé par les pairs

Résumé :

Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting.

Documents en relation

DI-fusion

Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar
par Agostinetto, Elisa , Curigliano, Giuseppe , Piccart-Gebhart, Martine
Publication 2024-06
The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial
par Debien, Véronique , Agostinetto, Elisa , Bruzzone, Marco , Ceppi, Marcello , Martins-Branco, Diogo , Molinelli, Chiara , Jacobs, Flavia , Marta, Guilherme Nader , Lambertini, Matteo Md Phd M. , de Azambuja, Evandro
Publication 2024-10-01
Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?
par Agostinetto, Elisa , Arecco, Luca , de Azambuja, Evandro
Publication 2024-03
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
par Agostinetto, Elisa , de Azambuja, Evandro , Lambertini, Matteo Md Phd M.
Publication 2023-12
Progression-free survival assessment by local investigators versus blinded independent central review in randomized clinical trials in metastatic breast cancer: A systematic review and meta-analysis
par Jacobs, Flavia , Molinelli, Chiara , Martins-Branco, Diogo , Marta, Guilherme Nader , Salmon, Maurine , Ameye, Lieveke , Piccart-Gebhart, Martine , Lambertini, Matteo Md Phd M. , Agostinetto, Elisa , de Azambuja, Evandro
Publication 2024-01-01

Référencement	Visibilité	Pérennité	Facilité
Les publications encodées constituent la bibliographie académique de l'Université.	Les documents déposés sont indexés par les moteurs de recherche (Google Scholar,…).	Les documents déposés en open-access sont archivés au sein du réseau de préservation SAFE-PLN (www.safepln.org).	Les listes de publications sont compatibles avec le CV-ULB, le FNRS et accessibles sur le web.